Overview

Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants

Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
The study will investigate the effect of single dose and multiple doses of M2951 on midazolam Pharmacokinetics (PK) in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Treatments:
Midazolam